SMMT Summit Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1599298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY15.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-220.0%
ROA-174.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-64.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| R&D expense | $537.67M | $150.78M |
| SG&A expense | $556.75M | $60.21M |
| Operating income | — | -$226.00M |
| Interest expense | $0 | $8.69M |
| Pretax income | -$1.08B | -$221.31M |
| Income tax | $0 | $0 |
| Net income | -$1.08B | -$221.31M |
| EBITDA | — | -$225.91M |
| EPS (basic) | -1.44 | -0.31 |
| EPS (diluted) | -1.44 | -0.31 |
| Weighted avg. shares (diluted) | 747.70M | 718.54M |
| Balance sheet | ||
| Cash & equivalents | $225.27M | $105.19M |
| Short-term investments | $488.18M | $307.49M |
| Current assets | $720.30M | $423.75M |
| PP&E, net | $1.06M | $254,000 |
| Goodwill | $2.00M | $1.86M |
| Intangibles | — | $0 |
| Total assets | $751.18M | $435.56M |
| Current liabilities | $72.99M | $41.73M |
| Total liabilities | $92.32M | $46.81M |
| Shareholders' equity | $658.86M | $388.75M |
| Shares outstanding | 775.37M | 737.63M |
| Cash flow statement | ||
| Operating cash flow | -$322.93M | -$142.11M |
| Capital expenditure | $657,000 | $139,000 |
| Free cash flow | -$323.59M | -$142.25M |
| Investing cash flow | -$174.31M | -$205.34M |
| Financing cash flow | $617.53M | $381.23M |
| Depreciation & amortization | $146,000 | $89,000 |
| Stock-based compensation | $732.42M | $50.98M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.